These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36344084)

  • 21. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Modifier genes and cystic fibrosis].
    Corvol H; Flamant C; Vallet C; Clement A; Brouard J
    Arch Pediatr; 2006 Jan; 13(1):57-63. PubMed ID: 16274977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
    Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A growing trend: CFTR modulators for cystic fibrosis lung transplant recipients.
    Hayes D; Sharma NS
    J Heart Lung Transplant; 2022 Feb; 41(2):127-128. PubMed ID: 34924264
    [No Abstract]   [Full Text] [Related]  

  • 25. Mutation-specific therapies and drug repositioning in cystic fibrosis.
    Villella VR; Tosco A; Esposito S; Bona G; Raia V; Maiuri L
    Minerva Pediatr; 2019 Jun; 71(3):287-296. PubMed ID: 30761820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR.
    Bose SJ; Krainer G; Ng DRS; Schenkel M; Shishido H; Yoon JS; Haggie PM; Schlierf M; Sheppard DN; Skach WR
    J Cyst Fibros; 2020 Mar; 19 Suppl 1(Suppl 1):S25-S32. PubMed ID: 31902693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
    Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
    Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.
    Mickle JE; Cutting GR
    Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simplifying CFTR modulation therapy in cystic fibrosis.
    Arch Dis Child; 2023 Aug; 108(8):615. PubMed ID: 37468145
    [No Abstract]   [Full Text] [Related]  

  • 30. Cystic Fibrosis: Highly Effective Targeted Therapeutics and the Impact on Sex and Racial Disparities.
    Montemayor K; Jain R
    Med Clin North Am; 2022 Nov; 106(6):1001-1012. PubMed ID: 36280328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging medicines to improve the basic defect in cystic fibrosis.
    Fajac I; Sermet-Gaudelus I
    Expert Opin Emerg Drugs; 2022 Sep; 27(3):229-239. PubMed ID: 35731915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining biologics and CFTR modulators is safe: A pilot, observational, monocenter study.
    Manti S; Giallongo A; Parisi GF; Papale M; Mulè E; Aloisio D; Rotolo N; Leonardi S
    Pediatr Pulmonol; 2024 Mar; 59(3):801-804. PubMed ID: 38014605
    [No Abstract]   [Full Text] [Related]  

  • 33. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.
    Shaw N; Collins S; Smith T; McCulloch A; Ketchell I; Edwards V; Blaikie L; Daniels T
    Br J Hosp Med (Lond); 2021 Nov; 82(11):1-6. PubMed ID: 34817261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic update in cystic fibrosis].
    Durupt S; Nove Josserand R; Durieu I
    Rev Med Interne; 2014 Jun; 35(6):388-92. PubMed ID: 24309546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.
    Boyle MP; De Boeck K
    Lancet Respir Med; 2013 Apr; 1(2):158-63. PubMed ID: 24429096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on new and emerging therapies for cystic fibrosis.
    Hudock KM; Clancy JP
    Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Important steps in the journey to highly effective CFTR modulator access for people with CF.
    VanDevanter DR; Mayer-Hamblett N
    J Cyst Fibros; 2019 Sep; 18(5):577-578. PubMed ID: 31500809
    [No Abstract]   [Full Text] [Related]  

  • 40. Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
    Lin S; Sui J; Cotard S; Fung B; Andersen J; Zhu P; El Messadi N; Lehar J; Lee M; Staunton J
    Assay Drug Dev Technol; 2010 Dec; 8(6):669-84. PubMed ID: 21050065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.